Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. Our therapeutic pipeline currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Our work is supported by an integrated suite of translational, clinical, and computational tools to generate insights that can enable precision medicine approaches. Neumora’s mission is to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients suffering from brain diseases.
Company profile
Ticker
NMRA
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
RBNC Therapeutics, Inc.
SEC CIK
Corporate docs
IRS number
844367680
NMRA stock data
Latest filings (excl ownership)
DEFA14A
Additional proxy soliciting materials
25 Apr 24
DEF 14A
Definitive proxy
25 Apr 24
8-K
Other Events
15 Apr 24
S-8
Registration of securities for employees
7 Mar 24
10-K
2023 FY
Annual report
7 Mar 24
8-K
Neumora Therapeutics Reports Fourth Quarter and Full Year 2023
7 Mar 24
8-K
Regulation FD Disclosure
8 Jan 24
8-K
Other Events
28 Nov 23
10-Q
2023 Q3
Quarterly report
1 Nov 23
8-K
Neumora Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
1 Nov 23
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | |
---|---|---|
Revenue | ||
Cost of revenue | ||
Operating income | ||
Operating margin | ||
Net income | ||
Net profit margin | ||
Cash on hand | ||
Change in cash | ||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | |||
---|---|---|---|---|---|---|
Cash on hand (at last report) | 825.78 mm | |||||
Cash burn (monthly) | 18.95 mm | |||||
Cash used (since last report) | 131.66 mm | |||||
Cash remaining | 694.12 mm | |||||
Runway (months of cash) | 36.6 |
Institutional ownership, Q3 2023
63.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 39 |
Opened positions | 39 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 472.61 bn |
Total shares | 101.45 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
AMGN AMGEN | 35.37 mm | $423.72 mm |
ARCH Venture Fund XII | 29.78 mm | $356.78 mm |
SFTBY Softbank | 7.65 mm | $107.90 bn |
FMR | 5.62 mm | $79.36 bn |
MIC Capital Management UK | 4.46 mm | $62.94 bn |
Wellcome Trust | 3.31 mm | $46.69 bn |
Artal | 2.80 mm | $39.55 mm |
Citadel Advisors | 2.17 mm | $29.70 bn |
EcoR1 Capital | 2.07 mm | $29.23 bn |
Avidity Partners Management | 1.80 mm | $25.40 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
22 Apr 24 | Daljit Singh Aurora | Common Stock | Gift | Dispose G | No | No | 0 | 114,703 | 0.00 | 97,500 |
14 Feb 24 | Joshua Pinto | Common Stock | Grant | Acquire A | No | No | 0 | 85,000 | 0.00 | 323,965 |
14 Feb 24 | Joshua Pinto | Stock Option Common Stock | Grant | Acquire A | No | No | 18.07 | 170,000 | 3.07 mm | 170,000 |
14 Feb 24 | Daljit Singh Aurora | Common Stock | Grant | Acquire A | No | No | 0 | 97,500 | 0.00 | 212,203 |
14 Feb 24 | Daljit Singh Aurora | Stock Option Common Stock | Grant | Acquire A | No | No | 18.07 | 195,000 | 3.52 mm | 195,000 |
14 Feb 24 | Carol Y. Suh | Common Stock | Grant | Acquire A | No | No | 0 | 85,000 | 0.00 | 374,674 |
14 Feb 24 | Carol Y. Suh | Stock Option Common Stock | Grant | Acquire A | No | No | 18.07 | 170,000 | 3.07 mm | 170,000 |
14 Feb 24 | Berns Paul L | Common Stock | Grant | Acquire A | No | No | 0 | 171,250 | 0.00 | 7,818,166 |
14 Feb 24 | Berns Paul L | Stock Option Common Stock | Grant | Acquire A | No | No | 18.07 | 342,500 | 6.19 mm | 342,500 |
News
S&P 500 Down Over 1%; US Retail Sales Increase 0.7% In March
15 Apr 24
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
15 Apr 24
Crude Oil Down 1%; Charles Schwab Sales Top Estimates
15 Apr 24
Why Is Neurology Focused-Neumora Therapeutics Shares Trading Lower On Monday?
15 Apr 24
Marinus Pharmaceuticals, Neumora Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session
15 Apr 24